Info session for NSF I-Corps

The NSF I-Corps program trains teams to use customer discovery and the Lean LaunchPad method to test their product-market fit.

Are you interested in finding out how the three evening program can significantly de-risk your startup venture? Join us for this short informational session on Tuesday, April 2.

This is also an opportunity to find like-minded people who are looking to build a team or join one. See you there!

The course itself will be held evenings of 4/29, 5/1, and 5/6 at UCSF Mission Bay Campus. Short applications are due April 12. Apply HERE if you already know you want to join the program.

Questions? Email gino.segre@ucsf.edu

Where and When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Tuesday, April 2, 4:00 to 6:00 PM

Questions? Email gino.segre@ucsf.edu

Meet One-on-One with Procter & Gamble at QB3

Procter & Gamble, the consumer goods company that owns brands such as Crest, Downy, Febreze, Head & Shoulders, Pantene, and Vicks, maintains its competitive edge through in-house innovation and partnerships to develop and acquire emerging technologies.

P&G is interested in meeting startups, and we are coordinating a partnering session on March 13 at UCSF Mission Bay.

Space is limited. If you would like to explore partnering with P&G, please apply online. Applications accepted thru Thursday, February 21.

Where & When

Suite 214, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Wednesday, March 13

Areas of Focus

P&G is interested in disruptive life science technologies for a healthy home ecosystem and environment. Below are the main areas of focus (download the detailed needs document):

• Malodor prevention, reduction or blocking; microbial population control.

• Non-prescription approaches to mitigate the negative physiological impacts of stress (solutions that would not be regulated as drugs) and maintain cardio-metabolic health (biomarkers, sensors, botanicals).

• Big (Omics) data analytics for identifying biomolecular targets for regulation of predetermined biological functions; for example, uprregulation of collagen or inhibition of inflammatory cytokines.

• Alternative methods for cost-effective production of short peptides up to 20 amino acids (fermentation or synthetic biology-based methods).

• Materials that have either of the following properties: block bitter taste; provide the sensation of pleasurable touch at the time of application to the skin; modulate trigeminal nerve-related sensations including pain, cooling, warming and itch; promote dermal regeneration to address gum recession, skin aging and vaginal atrophy; maintain healthy skin homeostasis and promote desirable skin feel.

Staying Younger Longer 2.0

As we age, our minds and bodies degenerate. Older people suffer pain, can't enjoy the activities they used to, forget things, and aren't as sharp mentally as younger people. But what if it were possible to slow this general decline and improve the quality of life for the aging? We would live in a happier and more productive society.

In recent years, QB3 has increasingly focused on aging-related disease. We've brought scientists together from Bay Area universities and the private sector. We want to spark productive collaborations that lead to understanding the process of aging and, ultimately, solutions to help all of us. This October, we've invited key players in the field to join us at an afternoon symposium at UCSF Mission Bay.

If you would like to learn about new research, meet leading scientists, connect to investors, and be a part of an exciting group that identifies and tackles one of the most important problems facing us today, please attend this symposium. Space is limited!

Slides

Susanna Rosi: Treatment Strategies to Prevent and Reverse Cognitive and Behavioral Deficits after Brain Injury

Tony Wyss-Coray: Plasma biomarkers for aging and Alzheimer’s Disease

Agenda

1:00 - 1:15 PM Registration

1:15 - 1:20 PM Reg Kelly (QB3): Introduction

Session I: Recent developments in understanding aging suggest that anti-aging therapies are on the horizon.

1:20 - 1:50 PM Eric Verdin (Buck Institute): "Therapy and Diagnostic Development at the Buck Institute"

1:50 - 2:10 PM Tony Wyss-Coray (Stanford): "Aging Factors in the Blood"

2:10 - 2:30 PM Susanna Rosi (UCSF): "Stress-Induced Acceleration of the Aging Process"

2:30 - 3:00 PM Coffee Break

Session II: To bring theory into practice we need biomarkers to predict disease, quantify disease progression and stratify age-related diseases.

3:00 - 3:20 PM Ron Kohanski (National Institute on Aging): "Biomarker Research"

3:20 - 3:35 PM Ben Kamens (Spring Discovery): "Applying AI Techniques to Data Analysis of Aging Biomarkers"

3:35 - 3:50 PM Kimberly Scearce-Levie (Denali Therapeutics): "Neurofilament as a Clinical Biomarker of Progression and Response"

3:50 - 4:05 PM Eric Morgen (BIOAGE): "From Longevity Biomarkers to Drug Targets"

Session III: We need to decide on the next steps to be taken for aging biomarkers.

4:05 - 5:15 PM Panel discussion: Supporting biomarker development for aging-related diseases. Moderator: Joe Betts-LaCroix (Vium)

• Laura Deming (Longevity Fund)

• Chris Haskell (Bayer)

• Ron Kohanski (NIA)

• John Newman (UCSF & Buck)

• James Peyer (Apollo Ventures)

5:15 - 5:30 PM Reg Kelly: Closing Remarks

5:30 - 7:00 PM Reception

Info session for NSF I-Corps short course

Find out about how participating in a three-evening NSF program known as "I-Corps" can significantly de-risk your startup venture. The program trains attendees to use customer discovery and the Lean LaunchPad method to test your product-market fit. Come to this information to get all your questions answered. This is also an opportunity to find like-minded people who are looking to build a team or join one. See you there!

The course will be held evenings of 10/15 (Mon), 10/17 (Wed), and 10/22 (Mon). Short applications are due October 10. Apply HERE if you already know you want to join the program.

Where and When

Monday, October 8, 4:30 to 6:00 PM
Room 215, Byers Hall, UCSF Mission Bay (1700 4th St.)

Questions? Email gino.segre@ucsf.edu

The Fifth Annual Rosenman Symposium on Health Technologies

The annual Rosenman Symposium is the premier event for the San Francisco Bay Area's health technology community. Join us to learn from leaders in the health technology industry, meet dynamic startups, and connect with hundreds of players in the Bay Area ecosystem.

For full information and registration, visit the symposium webpage on the Rosenman Institute website.

Agenda

Welcoming Remarks: Sam Hawgood, Chancellor, UCSF

Featured Speakers:

• Benson Smith, Chairman, Teleflex

• Tejal Desai, Chair, Department of Bioengineering & Therapeutic Sciences, UC San Francisco

• Joe DeSimone, CEO & Co-Founder, Carbon

• Jeffrey Shuren, Director, Center for Devices & Radiological Health, FDA

• Andrew Thompson, CEO, Proteus Digital Health

 
Panel Discussion: "The Future of Innovation in Health Technologies: Aligning All the Stakeholders"

Moderator: Josh Makower, General Partner, NEA

Panel Members:

• Tim Homer, VP Health Policy, Market Access & Government Affairs, iRhythm

• Wende Hutton, General Partner, Canaan Partners

• Kate Rosenbluth, CEO & Co-Founder, Cala Health

• Jeffrey Shuren, Director, Center for Devices & Radiological Health, FDA

• Renee Compton Ryan, VP, Venture Investments, J&J Innovation

 
With presentations by the 10 startup companies selected as the 2018 cohort of the Rosenman Innovators.
 
Reception to follow.

The Fourth Annual Rosenman Symposium

At the Rosenman Institute we’re here to support medtech startups. We connect entrepreneurs to the resources and expertise they need to commercialize their technologies. Helping innovators forge connections is why we’ve brought our legendary symposium back for a fourth year. Join us in San Francisco on June 21 to learn from leaders in the field, meet CEOs of exciting early-stage companies, and get insight on how industry forms strategic partnerships with startups.

Agenda

1:00 pm Registration

1:30 pm Welcome: Christine Winoto, Deputy Director, QB3; Director, Rosenman Institute

1:35 pm Steve Hetts, UCSF: "Hitting Cancer Hard While Limiting Collateral Damage"

1:55 pm Showcase: 2017 Rosenman Innovators

2:05 pm Justin Roberts, Medtronic: "TAVR: Developing and Cultivating a Breakthrough Therapy"

2:25 pm Showcase: 2017 Rosenman Innovators

2:35 pm Break

3:00 pm Robert Gaunt, University of Pittsburgh: "Wired Brains: Technology & Neuroscience for Rehabilitation"

3:20 pm Showcase: 2017 Rosenman Innovators

3:30 pm Richard Rapoza, Abbott Vascular: "Unexpected Consequences in Clinical Trial Design"

3:50 pm Showcase: 2017 Rosenman Innovators

4:00 pm Break

4:30 pm Panel Discussion: "Game of Thrones: Strategic Acquisition in Medtech"
Lisa Suennen, GE Ventures (moderator)
Jennifer Kozak, Johnson & Johnson
Chris Eso, Medtronic
Virginia Giddings, Stryker

5:30 pm Reception